At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
Nilotinibdrug
Likely dose
Nilotinib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multi-center, Open-label, Non-randomized Study of Nilotinib as First Line Treatment in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In Brief
A Phase 2 clinical trial evaluating Nilotinib for Chronic Myelogenous Leukemia. Completed, enrolled 112 participants across 13 sites.
Detailed Summary
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia (CML-CP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelogenous Leukemia
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartJan 2011
Primary CompletionAug 2019
TodayJul 2026
First PostedJan 11, 2011
Enrollment StartJan 25, 2011
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 15.5 years ago
Interventions
Nilotinibdrug
administered orally at a dose of 300 mg twice daily for 24 months